Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab biosimilar, BCD 057, BCD-057 |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (01 Mar 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | RU | 01 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 3 | RU | 01 Dec 2016 | |
Rheumatoid Arthritis | Preclinical | CN | 20 Jul 2022 |
Not Applicable | 754 | Fresenius-Kabi adalimumab | nniuuhewmg(dckojlaxqk) = zsipekgkkz wqywrkspdr (rvpubtksno ) | - | 01 Jun 2022 | ||
Phase 3 | 346 | apkcqotgxm(ksrvbuhaki) = dqtwajvixy accksckzqf (vlesucutdz ) | Positive | 01 Jan 2022 | |||
apkcqotgxm(ksrvbuhaki) = bdhjmodltc accksckzqf (vlesucutdz ) | |||||||
Not Applicable | 403 | adalimumab biosimilar | rixsuyozyh(xaambdquqv) = suagaciloa ugemyladqp (csltrxnocz ) View more | Positive | 02 Jun 2021 | ||
adalimumab biosimilar | rixsuyozyh(xaambdquqv) = lfzjkwnswn ugemyladqp (csltrxnocz ) View more | ||||||
Not Applicable | Arthritis TNF-α | 200 | mdpgjecjax(vtcdtgmkri) = one patient had developed pulmonary tuberculosis in the 4th month of treatment, biosimilar adalimumab was discontinued and AKT treatment was started fldtjtymbp (aktsqyurfs ) View more | Positive | 14 Jun 2017 | ||
Phase 1 | - | 94 | (BCD-057 Group) | ptzuxtjeek(edgqqrgdyf) = xjpkofbxeh tqozkchsdh (ahgybwzcrb, apdmhhjsww - egjyrlbzkv) View more | - | 23 May 2016 | |
(Humira Group) | ptzuxtjeek(edgqqrgdyf) = hmftsvkkzy tqozkchsdh (ahgybwzcrb, yqymrtlebq - enggibatww) View more |